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Cyclins are indispensable elements of the cell cycle and derangement of their function can lead to cancer forma-
tion. Recent studies have also revealed more mechanisms through which cyclins can express their oncogenic
potential. This review focuses on the aberrant expression of G1/S cyclins and especially cyclin D and cyclin E; the
pathways through which they lead to tumour formation and their involvement in different types of cancer. These
elements indicate the mechanisms that could act as targets for cancer therapy.
Introduction
Cyclins are proteins which act as key controlling ele-
ments of the eukaryotic cell cycle. These proteins have
some regions of homology such as the cyclin box and
some other islands of homology outside the cyclin box
[1]. In mammalian cells, cyclins bind to cyclin depen-
dent kinases and form complexes that are involved in
regulating different cell cycle transitions: cyclin-D-
CDK4/6 complex for G1 progression, cyclin- E - CDK2
for the G1-S transition, cyclin-A-CDK2 for S phase pro-
gression and cyclin A/B-CDC2 for entry into M-phase.
In addition to these functions, cyclins are also involved
in some processes not directly related to the cell cycle.
The importance of cyclin-CDK complexes in cell prolif-
eration is underscored by the fact that deregulation in
the function of these complexes is found in virtually the
whole spectrum of human tumors and this comes from
the fact that tumor-associated alterations in cyclins help
to sustain proliferation independently of external mito-
genic or anti-mitogenic signals [2]. In this review we are
going to deal with the role of cyclins D and E in the
development of cancer, since these cyclins have proved
to be of great importance for cancer pathogenesis.
Cyclins and cell cycle
Considerable effort over many years has been expended in
order to understand the mechanisms that control normal
cell cycles. This effort has resulted in a detailed - but not
yet completed - picture of the cell cycle revealing that
complex oscillations in the activation and inactivation of
cyclin- dependent kinase complexes propel mammalian
cells through the cycle. The levels of most CDKs are rela-
tively constant during the cell cycle but their activities
depend highly on the state and level of activation of their
cyclin partners or other regulatory molecules [3].
The triggering factor for progression to S phase is a
mitogenic signal. In response to mitogenic activation,
cells synthesize D-type cyclins which form a holoenzyme
with CDK4, CDK6. Cyclin D1 is the regulatory subunit
whereas the CDKs are the catalytic subunit (figure 1).
This assembly of proteins needs members of the Cip/Kip
families of proteins which promote the activity of cyclin
D dependent kinases and serve as inhibitors of CDK2.
[4]. The active complex phosphorylates the pRB protein
and leads to its inactivation. The inactivated pRB protein
seperates from the complex of pRB and E2F transcription
factors giving permission to genes required for S phase to
be transcripted [3]. Cyclin E, cyclin A and DNA pol
stand among these genes. Cyclin E binds to CDK2 lead-
ing to phosphorylation of substrates required for proper
replication firing, centrosome duplication and histone
biosynthesis [5]. Cyclin E and its partner, CDK2, can also
further phosphorylate and inactivate pRB. Cyclin A binds
to CDK2 and this complex phosphorylates CDC6 result-
ing in its relocalisation from the nucleus to the cytoplasm
and in this way to its destruction. This procedure pre-
vents CDC6 from assembling into origins of replication
of DNA after G1. DNA re- replication is also avoided by
the procedure where cyclin A -CDK2 phosphorylates
MCM4 in the helicase complex and eventually inhibits
its DNA helicase activity [6].
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on expression and activation of cyclin/CDK complexes
permit exquisite and necessary coordination of the cell
cycle stages and thereby prevent from the formation of
tumor cells [2].
Cyclin D and cancer
Cyclin D is solidly established as an oncogene with an
important pathogenetic role in many human tumors.
There are three highly homologous and almost indistin-
guishable biochemically D- type cyclins (D1, D2 and
Figure 1 Cyclins and cell cycle regulation. This figure is a schematic presentation of the roleof cyclins in the cell cycle.
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C D K 4o rC D K 6i nat i s s u es p e c i f i cw a y .A m o n gt h e s e
types, cyclin D1 is the one most commonly expressed in
several human cancers [6]. Cyclin D1 is a 35-kDa pro-
tein which is encoded by 5 exons situated at the region
of chromosome band 11q13. In the aminoterminus of
cyclin D1 appears a motif Leu - X - Cys - X - Glu (X
represents any aminoacid) where pRB pocket domain
binds. The carboxy terminus inhibits myogenic helix
loop helix (HLH) protein function. HLH protein main
action is to remove cells from the cell cell cycle (halt
proliferation), so its inhibition by cyclin D1 leads the
cell to G1 stage of the cell cycle. Repression by D
cyclins appears to be independent of its effects on the
cell cycle [7]. The protein is quite unstable with a half -
life of less than 20 minutes; its degradation is ubiquitin
proteosome- regulated [8].
Cyclin D1 is overexpressed in several human tumours.
Chromosomal translocations, gene amplification and
disruption of normal intercellular trafficking and proteo-
lysis are the procedures which lead to accumulation of
cyclin D1 in tumor cell nuclei and eventually to cyclin
D1 overexpression in many tumours.
Chromosomal translocations are very common among
parathyroid adenomas, B mantle cell lymphomas and
multiple myelomas. Gene amplification (11q13) as a
mechanism for aberrant overexpression of cyclin D1 is
associated with non- small cell lung cancers, head and
neck squamous cell carcinomas, pancreatic carcinomas,
bladder cancer, pituitary adenomas and breast carci-
noma. Emerging evidence suggests that nuclear reten-
tion of cyclin D1 resulting from altered nuclear
trafficking and proteolysis is critical for the manifesta-
tion of its oncogenicity [9]. Disruption of the normal
intracellular trafficking and proteolysis of the nuclear
non - phosphorylatable cyclin results from a polymorph-
ism in exon four of cyclin D1. This leads to a C-termi-
nus that lacks the phosphor- acceptor site that targets
cyclin D1 for cytoplasmic destruction [10].
Cyclin D oncogenic potential is manifested in several
ways. As mentioned before, it leads to direct activation
of CDK4/6. In addition to this function, cyclin D1/CDK
complexes bind and sequester p21CIP1 and p27KIP1,
which among others function as inhibitors of cyclin E/
CDK2. [11]. In this way, both high expression of cyclin
D1 and deregulated expression of cyclin E1 cooperate to
increase tumour fitness. Another cyclin D1 function that
can lead to tumour formation is the transcriptional con-
trol that does not involve CDKs. This function involves
promoter recruitment of histone deacetylases (HDACs)
and histone methyltransferases. Normally HDAC, by
increasing the positive charge of histone tails and
histone methylotransferases, through the methylation
of histones, can both lead to high- affinity binding
between histones and DNA backbone. In this way, DNA
structure condenses and transcription is prevented [12].
Several groups have demonstrated that cyclin D1 can
also act as a transcriptional co-factor for steroid hor-
mone receptors such as estrogen receptor [13].
Besides tumour formation, cyclin D1 can also play a
pivotal role in the invasiveness and the metastatic phe-
notype through the interactions between the malignant
cell and the host environment. For example, overexpres-
sion of cyclin D1 through the activation of positive feed-
back loop of E2F-1 mediated transcription can lead to
excessive expression of FGFR-1 (fibroblast growth factor
receptor 1) [14]. FGFR up - regulation has been shown
in several tumours such as brain, breast, prostate, thyr-
oid, skin and salivary gland tumours. Additionally, cyclin
D1 normally plays a regulatory role in angiogenesis and
mithochondrial function. This suggests that deregulated
cyclin D1 expression can contribute to the invasive and
metastatic potential of a tumour, since mtDNA muta-
tions can lead to development of metastases by overpro-
duction of reactive oxygen species (ROS) [15,16].
The biological importance of these functions needs
to be proved in vivo; nevertheless it is obvious in con-
cept that they could be of variable impact on tumour
phenotype. Nevertheless, solitary cyclin overexpression
is not sufficient for malignancy transformation. Addi-
tional cellular abnormalities are necessary for the
tumour formation [17].
Table 1 describes the way that cyclin D is associated
with several types of cancer.
Parathyroid adenomas are a common disease where
cyclin D1 is overexpressed. The pericentromeric inver-
sion of chromosome 11 places the 5’ regulatory region
of the PTH gene on 11p15 immediately upstream of
cyclin D1 gene promoter. Many studies have taken place
and they have demonstrated a cyclin D1 overexpression
which varies between 20 - 40% [18]. Nevertheless, over-
expression of cyclin D1 is also found in nonneoplastic
proliferation of parathyroid gland, but not in the normal
parathyroid tissue. The hormonal regulatory defect in
parathyroid adenomas can be both primary and second-
ary to a defect in cellular - growth control indicated by
cyclin D1 oncogene overexpression [19].
Papillary thyroid carcinoma is another malignant
tumour where cyclin D1 is overexpressed. In addition to
this, the level of cyclin D1 expression according to
lymph node metastasis was statistically significant (P <
0.05). This fact indicates that cyclin D1 may be a useful
marker for the evaluation of lymph node metastasis
In addition to solid tumours, overexpression of cyclin
D1 has also been reported in certain lymphoid malig-
nancies. Referring to B- cell non Hodgkin lymphomas,
cyclin D1 was mainly overexpressed in mantle cell lym-
phomas and large B- cell lymphomas whereas the other
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signs (except for lymphadenopathy) and laboratory data
(except for LDH) were not influenced by cyclin D1
overexpression which, nevertheless, proved to be asso-
ciated with poor outcome of NHL patients [20]. More
specifically, mantle cell lymphoma, which accounts for
5 - 10% of all non Hodgkin lymphomas, demonstrate
chromosome translocations (t(11;14)) involving the
immunoglobulin heavy chain IgH locus that lead to
cyclin D1 deregulation [21]. Mantle cell lymphomas
express variable levels of cyclin D1 at both transcript
and protein levels. Overexpression of cyclin D2 and D3
has also been described. As far as mRNA forms pro-
duced by cyclin D1 gene (long - D1L, short - D1S) are
concerned, the short version has been shown to be
more related to blastoid histology than the long version
(60% of D1 S and 9% of D1L) [22]. In addition to these
notifications, cyclin D1 was also identified as a poten-
tially important antigen for immunotherapy of mantle
cell lymphoma as it was proved to be recognized by
potent cytotoxic T cells when it was naturally presented
by lymphoma cells in the context of HLA - A * 0201
molecules [23]. Another subtype of non Hodgkin lym-
phomas, known as diffuse large B - cell lymphoma,
shows overexpression of D1 (2%) D2 (49%) and D3
(20%) cyclins [24]. A small subset of chronic lymphocy-
tic leukemias overexpresses cyclin D1 in amounts that
can be demonstrated by immunohistochemistry [25].
Cyclin D1 is solidly established as an oncogene with a
pivotal role in pathogenesis of breast cancer. Besides
gene amplification, cytoplasmic sequestration may also
serve to regulate cyclin D1 activity in mammalian cancer
cells [26]. Emerging evidence indicates that cyclin D1
may act, in part, through pathways which do not involve
its role as a cell cycle regulator. One such function is
the cyclin D1 contribution to cell adhesion and motility.
So, it was demonstrated that cyclin D1/CDK4 complex
interacts with filamin A (member of the actin - binding
filamin protein family) and influences the migration and
invasion potential of breast cancer cells [27]. CCDN1
amplification is found in 5 - 20% of primary breast can-
cers [28].
Cyclin E and cancer
Human cyclin E cDNA was identified in 1991 by screen-
ing human cDNA libraries for genes that could comple-
ment G1 cyclin mutations in yeast S. cerevisiae [29].
Cyclin E is derived from a gene on chromosome 19q12
® q13. This gene encodes a variety of polypeptides with
molecular weights ranging from 39 to 52 kDa. The “reg-
ular” form contains the “cyclin box”,as e q u e n c es e ti n
amino acid position 129-215, which is partly common
among the cyclins. In addition to the regular form, two
splice variants and an isoform with 15 additional ami-
noacids at the N-terminus have also been described
[30]. More recently six splice variants with the potential
to produce cyclin E isoforms of substantially altered
molecular weight have been found [31]. All splice var-
iants with an intact cyclin box have the ability of bind-
ing and activation of CDK2 [32].
The deregulated expression and activity of cyclin E
have been associated with a variety of cancers and it is
considered to be involved in the oncogenic process [33].
The oncogenic activity of cyclin E is a result of several
mechanisms. Cell cycle deregulation of cyclin E expres-
sion is common in some tumour cells leading to consti-
tutive cyclin E expression and activity throughout the
cell cycle. Overexpression of cyclin E can come from
gene amplification in most cases [34]. For example
cyclin E gene is amplified by 8 fold and its mRNA is
Table 1 The role of cyclin D in several types of cancers
Parathyroid adenomas Cyclin D overexpression in both neoplastic and non- neoplastic proliferating parathyroid tissue.
Papillary thyroid carcinoma lymph node metastasis
Mantle cell lymphoma Higher age distribution
Larger cell size
Higher mitotic index
More frequent gastrointestinal involvement
Higher international prognostic index score
Lower p27 expression
Significantly worse survival
breast cancer higher tumour grade
no correlation with axillary lymph node status or tumour size or HER2 amplification
poorer prognosis
indication for need for additional chemotherapeutic treatment
positive correlation with ER status (p < 0.005)
positive correlation with PR status (p < 0.005)
inverse correlation to Nottingham prognostic index
inverse correlation to membrane EGFR
significantly shorter overall survival and relapse - free survival
tamoxifen resistance
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lines [35,36]. Defected degradation via the proteosome is
another mechanism leading to cyclin E overexpression;
the F- box proteins that target cyclin E for ubiquitination
and as a result for degradation were discovered to be
mutated in some cancers [37]. Cyclin E overexpression
can lead to G1 shortening, decrease in cell size or loss of
serum requirement for proliferation. This is the conse-
quence of cyclin E normal function of S - phase induc-
tion; one of the pathways involving pRB has already been
described; in addition cyclin E/CDK2 complexes have
been proved to activate transcriptional regulators like
human B - MYB and NPAT which are of great impor-
tance for cellular proliferation [38]. Besides the mechan-
isms already described, cyclin E demonstrates its
oncogenic potential by a correlation with oncogenic
viruses. HPV and especially HPV E7 protein which is
implicated in cervix carcinoma, can lead to promotion of
cyclin E - associated kinase activities through the interac-
tion with p21 (which is a cyclin - dependent kinase inhi-
bitor) [39]. CMV has a dual role in activating cyclin E
through direct induction of cyclin E and inactivation of
cyclin - dependent kinase inhibitors [40]. On the other
hand, HIV - 1 halts cyclin E activity and causes G1 phase
arrest, which encourages viral replication [41].
Cyclin E is a factor found in a variety of cancers like
breast, ovarian, colorectal, bladder and other. In Table 2
the way cyclin E is associated with several types of can-
cer is depicted.
With regard to breast cancer, a remarkable number of
studies have been driven. Altered expression of cyclin E
occurs in 18 - 22% of the breast cancers and can serve
Table 2 Cyclin E and its role in different types of cancer




Lack of steroid receptors
HER - 2/neu expression
Ki - 67 expression
BRCA1 germline mutations
Triple negative breast tumours
Basal - type keratins (CK 5/6 or CK17) expression
Bone, visceral and in general distant relapse
Ovarian Cancer Controversial correlation with prognosis
Serous, clear cell and poorly differentiated carcinomas
Higher tumour grade
Late stage disease
Patient age more than 60 years old at the time of diagnosis
Suboptimal cytoreduction
Controversial correlation with lifetime ovulatory cycles (LOC)
No correlation with the chemotherapy response
Marker of aggressive disease in patients with metastatic ovarian carcinoma (low molecular weight isoforms)
Gastric cancer Promotion of the progression of early gastric cancer




Tumour size (p > 0.05)
Lymphatic invasion
CDK - 2 expression
pRb expression
Colorectal carcinomas Increased risk of recurrence
Worse outcome
Possible prognostic marker in non metastatic colon cancer
Correlation with p21 waf1/cip1 and cell proliferation
Blood vessel invasion
Gross configuration of the tumour
Independent prognostic factor in rectal carcinoma at stage I - III
Melanomas Histological type
Tumour stage
Significant association with some specific tumour subtypes
Non small cell lung carcinoma Poorer survival among stage I to IIIa
Invasion of local structures
Poor prognosis
Ki - 67 labeling index
Distant metastases
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low molecular weight cyclin E derivatives has been
investigated with great emphasis since they have been
shown to be of great pathogenetic and prognostic
importance for breast cancer. Low molecular weight iso-
forms are resistant to CKIs, bind more efficiently to
CDK2 and can stimulate the cells to progress through
the cell cycle more efficiently [43,44]. As a result resis-
tance to anti - growth signals and genomic instability
are more common. These forms have proved to be a
remarkable marker of the prognosis of early -stage -
node negative breast carcinoma [45].
Cyclin E has also been correlated with ovarian carci-
nomas, the fourth leading cause of cancer deaths among
women in the United States. In ovarian carcinomas,
cyclin E is overexpressed primarily in the low molecular
weight isoforms [46] which are both biochemically and
biologically hyperactive as mentioned before. The exact
correlation between cyclin E overexpression and prog-
nosis is controversial.
Cyclin E overexpression is also implicated in carcino-
mas at various sites along the gastrointestinal tract, but
the most important sites are the stomach and the color-
ectal region [47]. As far as stomach cancers are con-
cerned, cyclin E overexpression was found in 50 - 60%
of gastric adenomas and adenocarcinomas [48]. Cyclin E
was shown to be of independent prognostic significance
in gastric carcinoma [49].
Regarding the colorectal carcinomas, cyclin E gene
amplification is quite rare, estimated at the level of 10%
[50]. Overexpression of cyclin E is detected in the early
stages of the carcinogenic process promoting the mor-
phological progression from adenoma to adenocarci-
noma and the progression of early cancer [50,51]. Cyclin
E was detected in both full length and low molecular
weight forms in tumour and adjacent macroscopically
normal mucosa.
Cyclin E overexpression has also been reported in
melanomas. Cyclin E, in combination with other cell
cycle regulators, has been proved to be of determinant
significance for melanoma growth and/or transformation
and this is indicared by the fact that cyclin E was not
detected in benign naevi but it was easily detectable in
most of the metastatic melanomas [52]. Another study
has explicated the importance of the low molecular
weight isoforms of cyclin E in melanoma formation. It
was found that the isoforms were overexpressed in a
subset of primary invasive and in metastatic melanomas
but not in benign naevi. The low molecular weight
forms are histologically active and can function as regu-
lators of invasion and metastasis since they can form
angiogenic tumors with prominent perineural invasion
and increase the incidence of metastases in comparison
to the full - length cyclin E [53].
Implication of cyclin E in the non small cell lung
carcinomas has been the subject of several studies. The
association with deeply invasive tumours and the func-
tion of cyclin E as an independent factor for poor prog-
nosis were also proved by another study [54].
Conclusions
In conclusion, cyclins play a multifunctional and pivotal
role in the pathogenesis of cancer. This is the reason
why alterations in their structure and function through
the influence of various pathways can lead to an array
of cancer types. This discovery in combination with
recent studies in genetically engineered mouse models
implies their potential role in cancer therapy and espe-
cially targeted therapies. Despite the clinical applications
of cell cycle specific chemotherapeutic agents there is
still urgent need to develop novel drugs that are able to
target multiple sites and pathways of the cell cycle [55].
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